Radioimmunotherapy for peritoneal cancers

Immunotherapy

Volumn 5, Issue 4, 2013, Pages 395-405

  Seidl, Christof ^a   Essler, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

emitter; emitter; antibody; Auger emitter; intraperitoneal tumor; radionuclide; targeted therapy

Indexed keywords

ACTINIUM 225; ANTIBODY CONJUGATE; ASTATINE 211; BISMUTH 213; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COPPER 67; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IODINE 131; LEAD 212; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MN14; MONOCLONAL ANTIBODY MX35; PACLITAXEL; RHENIUM 186; TETRAXETAN; TRASTUZUMAB; UNCLASSIFIED DRUG; YTTRIUM 90;

ALPHA RADIATION; AUGER ELECTRON SPECTROSCOPY; CANCER CELL CULTURE; CANCER MODEL; CARCINOMATOUS PERITONITIS; CELL KILLING; COLON CANCER; CYTOREDUCTIVE SURGERY; ELECTRON; HUMAN; KIDNEY TUBULE EPITHELIUM; MICROMETASTASIS; NONHUMAN; OVARY CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TUMOR XENOGRAFT;

COLONIC NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES;

EID: 84875948186     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.20     Document Type: Review

References (67)

1. Levy AD, Shaw JC, Sobin LH. Secondary tumors and tumorlike lesions of the peritoneal cavity: Imaging features with pathologic correlation. Radiographics 29, 347-373 (2009).
2. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 63, 364-367 (1989).
3. Sadeghi B, Arvieux C, Glehen O et al. Peritoneal carcinomatosis from nongynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 88, 358-363 (2000).
4. Gunn AJ, Brechbiel MW, Choyke PL. The emerging role of molecular imaging and targeted therapeutics in peritoneal carcinomatosis. Expert. Opin. Drug Deliv. 4, 389-402 (2007).
5. Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br. J. Cancer 69, 235-241 (1994).
6. Elias D, Blot F, El Otmany A et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92, 71-76 (2001).
7. Kouloulias VE, Nikita KS, Kouvaris JR et al. Cytoreductive surgery combined with intraoperative chemo-hyperthermia and postoperative radiotherapy in the management of advanced pancreatic adenocarcinoma: Feasibility aspects and efficacy. J. Hepatobiliary Pancreat. Surg. 8, 564-570 (2001).
8. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34-43 (2006).
9. Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 113, 631-636 (1993).
10. Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J. Surg. Oncol. 85, 61-67 (2004).
11. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: New prospects for antibodies and immunoconjugates. CA Cancer J. Clin. 56, 226-243 (2006).
12. Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumour Biol. 33, 573-590 (2012).
13. Horak E, Hartmann F, Garmestani K et al. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J. Nucl. Med. 38, 1944-1950 (1997).
14. Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 63, 5084-5090 (2003).
15. Song EY, Qu CF, Rizvi SM et al. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol. Ther. 7, 76-80 (2008).
16. Palm S, Bäck T, Claesson I et al. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int. J. Radiat. Oncol. Biol. Phys. 69, 572-579 (2007).
17. Elgqvist J, Andersson H, Bäck T et al. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J. Nucl. Med. 47, 1342-1350 (2006).
18. Elgqvist J, Andersson H, Haglund E et al. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities. Cancer Biother. Radiopharm. 24, 509-513 (2009).
19. Elgqvist J, Andersson H, Jensen H et al. Repeated intraperitoneal alpharadioimmunotherapy of ovarian cancer in mice. J. Oncol. 2010, 394913 (2010).
20. Gustafsson AM, Bäck T, Elgqvist J et al. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model. Nucl. Med. Biol. 39, 15-22 (2012).
21. Meredith RF, Buchsbaum DJ, Alvarez RD, LoBuglio AF. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. Clin. Cancer Res. 13(18 Pt 2), S5643-S5645 (2007).
22. Borchardt PE, Quadri SM, Freedman RS, Vriesendorp HM. Intraperitoneal radioimmunotherapy with human monoclonal IgM in nude mice with peritoneal carcinomatosis. Cancer Biother. Radiopharm. 15, 53-64 (2000).
23. Knogler K, Grünberg J, Zimmermann K et al. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Clin. Cancer Res. 13(2 Pt 1), 603-611 (2007).
24. Fischer E, Grünberg J, Cohrs S et al. L1-CAM-targeted antibody therapy and 177Lu-radioimmunotherapy of disseminated ovarian cancer. Int. J. Cancer 130, 2715-2721. (2012).
25. Zacchetti A, Martin F, Luison E et al. Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5.3 in a mouse model for ovarian cancer. J. Nucl. Med. 52, 1938-1946 (2011).
26. Milenic DE, Garmestani K, Brady ED et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin. Cancer Res. 10, 7834-7841 (2004).
27. Milenic DE, Garmestani K, Brady ED et al. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a 212Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother. Radiopharm. 20, 557-568 (2005).
28. Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. 212Pb-radioimmunotherapy induces G2 cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol. Cancer Ther. 11, 639-648 (2012).
29. Milenic DE, Garmestani K, Brady ED et al. Potentiation of high-LET radiation by gemcitabine: Targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin. Cancer Res. 13, 1926-1935 (2007).
30. Milenic DE, Garmestani K, Brady ED et al. Multimodality therapy: Potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin. Cancer Res. 14, 5108-5115 (2008).
31. Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW. Improved efficacy of alpha-particle-targeted radiation therapy: Dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. Cancer 116(Suppl. 4), 1059-1066 (2010).
32. Esteban JM, Hyams DM, Beatty BG, Merchant B, Beatty JD. Radioimmunotherapy of human colon carcinomatosis xenograft with 90Y-ZCE025 monoclonal antibody: Toxicity and tumor phenotype studies. Cancer Res. 50(Suppl. 3), S989-S992 (1990).
33. Koppe MJ, Bleichrodt RP, Soede AC et al. Biodistribution and therapeutic efficacy of 125/131I-, 186Re-, 88/90Y-, or 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J. Nucl. Med. 45, 1224-1232 (2004).
34. Koppe MJ, Oyen WJ, Bleichrodt RP, Verhofstad AA, Goldenberg DM, Boerman OC. Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Cancer Biother. Radiopharm. 21, 506-514 (2006).
35. Kinuya S, Li XF, Yokoyama K et al. Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy. Cancer Sci. 94, 650-654 (2003).
36. Kinuya S, Yokoyama K, Fukuoka M et al. Intraperitoneal radioimmunotherapy to treat the early phase of peritoneal dissemination of human colon cancer cells in a murine model. Nucl. Med. Commun. 28, 129-133 (2007).
37. Koppe MJ, Hendriks T, Boerman OC, Oyen WJ, Bleichrodt RP. Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J. Nucl. Med. 47, 1867-1874 (2006).
38. Aarts F, Bleichrodt RP, de Man B, Lomme R, Boerman OC, Hendriks T. The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat. Ann. Surg. Oncol. 15, 3299-3307 (2008).
39. Ray GL, Baidoo KE, Keller LM, Albert PS, Brechbiel MW, Milenic DE. Pre-clinical assessment of Lu-labeled trastuzumab targeting HER2 for treatment and management of cancer patients with disseminated intraperitoneal disease. Pharmaceuticals (Basel) 5, 1-15 (2011).
40. Buchsbaum DJ, Khazaeli MB, Axworthy DB et al. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein. Clin. Cancer Res. 11, 8180-8185 (2005).
41. Seidl C, Senekowitsch-Schmidtke R. Treatment of diffuse-type gastric cancer cells using 213Bi-radioimmunoconjugates in vitro and in vivo following intraperitoneal dissemination. Curr. Radiopharm. 1, 215-224 (2008).
42. Senekowitsch-Schmidtke R, Schuhmacher C, Becker KF et al. Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpharadioimmunotherapy of diffuse-type gastric cancer. Cancer Res. 61, 2804-2808 (2001).
43. Huber R, Seidl C, Schmid E et al. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody. Clin. Cancer Res. 9(10 Pt 2), S3922-S3928 (2003).
44. Beck R, Seidl C, Pfost B et al. 213Biradioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice. Cancer Sci. 98, 1215-1222 (2007).
45. Buchhorn HM, Seidl C, Beck R et al. Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging. Eur. J. Nucl. Med. Mol. Imaging 34, 841-849 (2007).
46. Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a Bi-conjugated monoclonal antibody. Clin. Cancer Res. 11(19 Pt 2), S7070-S7074 (2005).
47. Seidl C, Zöckler C, Beck R, Quintanilla-Martinez L, Bruchertseifer F, Senekowitsch-Schmidtke R. 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to Biimmunotherapy, but causes toxicity not observed with Bi. Eur. J. Nucl. Med. Mol. Imaging 38, 312-322 (2011).
48. Boudousq V, Ricaud S, Garambois V et al. Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies. J. Nucl. Med. 51, 1748-1755 (2010).
49. Baranowska-Kortylewicz J. Intraperitoneal radioimmunotherapy: Auger electron emitters for solid tumors. Immunotherapy 3, 491-494 (2011).
50. Andersson H, Cederkrantz E, Bäck T et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: Pharmacokinetics and dosimetry of 211At-MX35 F(ab')2 - a Phase I study. J. Nucl. Med. 50, 1153-1160 (2009).
51. Yin BW, Kiyamova R, Chua R et al. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun. 8, 3 (2008).
52. Finstad CL, Lloyd KO, Federici MG et al. Distribution of radiolabeled monoclonal antibody MX35 F(ab')2 in tissue samples by storage phosphor screen image analysis: Evaluation of antibody localization to micrometastatic disease in epithelial ovarian cancer. Clin. Cancer Res. 3, 1433-1442 (1997).
53. Rubin SC, Kostakoglu L, Divgi C et al. Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer. Gynecol. Oncol. 51, 61-66 (1993).
54. Stewart JS, Hird V, Sullivan M, Snook D, Epenetos AA. Intraperitoneal radioimmunotherapy for ovarian cancer. Br. J. Obstet. Gynaecol. 96, 529-536 (1989).
55. Epenetos AA, Hird V, Lambert H, Mason P, Coulter C. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int. J. Gynecol. Cancer 10(Suppl. 1), 44-46 (2000).
56. Verheijen RH, Massuger LF, Benigno BB et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J. Clin. Oncol. 24, 571-578 (2006).
57. Oei AL, Verheijen RH, Seiden MV et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int. J. Cancer 120, 2710-2714 (2007).
58. Mahé MA, Fumoleau P, Fabbro M et al. A Phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin. Cancer Res. 5(Suppl. 10), S3249-S3253 (1999).
59. Rosenblum MG, Verschraegen CF, Murray JL et al. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: Effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin. Cancer Res. 5, 953-961 (1999).
60. Meredith RF, Partridge EE, Alvarez RD et al. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J. Nucl. Med. 37, 1491-1496 (1996).
61. Alvarez RD, Partridge EE, Khazaeli MB et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: A Phase I/II study. Gynecol. Oncol. 65, 94-101 (1997).
62. Alvarez RD, Huh WK, Khazaeli MB et al. A Phase I study of combined modality 90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin. Cancer Res. 8, 2806-2811 (2002).
63. Meredith R, You Z, Alvarez R, Partridge E, Grizzle W, LoBuglio A. Predictors of longterm outcome from intraperitoneal radioimmunotherapy for ovarian cancer. Cancer Biother. Radiopharm. 27, 36-40 (2012).
64. Apostolidis C, Molinet R, McGinley J, Abbas K, Möllenbeck J, Morgenstern A. Cyclotron production of Ac-225 for targeted alpha therapy. Appl. Radiat. Isot. 62, 383-387 (2005).
65. Haddad F, Barbet J, Chatal JF. The ARRONAX project. Curr. Radiopharm. 4, 186-196 (2011).
66. Chouin N, Bardiès M. Alpha-particle microdosimetry. Curr. Radiopharm. 4, 266-280 (2011).
67. Sgouros G, Hobbs RF, Song H. Modelling and dosimetry for alpha-particle therapy. Curr. Radiopharm. 4, 261-265 (2011).